Microglia degrade Tau oligomers deposit via purinergic P2Y12-associated podosome and filopodia formation and induce chemotaxis.
Filopodia
Microglia
Migration
P2Y12
Podosome
Tau oligomers
Journal
Cell & bioscience
ISSN: 2045-3701
Titre abrégé: Cell Biosci
Pays: England
ID NLM: 101561195
Informations de publication
Date de publication:
23 May 2023
23 May 2023
Historique:
received:
20
10
2022
accepted:
02
04
2023
medline:
24
5
2023
pubmed:
24
5
2023
entrez:
23
5
2023
Statut:
epublish
Résumé
Tau protein forms neurofibrillary tangles and becomes deposited in the brain during Alzheimer's disease (AD). Tau oligomers are the most reactive species, mediating neurotoxic and inflammatory activity. Microglia are the immune cells in the central nervous system, sense the extracellular Tau via various cell surface receptors. Purinergic P2Y12 receptor can directly interact with Tau oligomers and mediates microglial chemotaxis via actin remodeling. The disease-associated microglia are associated with impaired migration and express a reduced level of P2Y12, but elevate the level of reactive oxygen species and pro-inflammatory cytokines. Here, we studied the formation and organization of various actin microstructures such as-podosome, filopodia and uropod in colocalization with actin nucleator protein Arp2 and scaffold protein TKS5 in Tau-induced microglia by fluorescence microscopy. Further, the relevance of P2Y12 signaling either by activation or blockage was studied in terms of actin structure formations and Tau deposits degradation by N9 microglia. Extracellular Tau oligomers facilitate the microglial migration via Arp2-associated podosome and filopodia formation through the involvement of P2Y12 signaling. Similarly, Tau oligomers induce the TKS5-associated podosome clustering in microglial lamella in a time-dependent manner. Moreover, the P2Y12 was evidenced to localize with F-actin-rich podosome and filopodia during Tau-deposit degradation. The blockage of P2Y12 signaling resulted in decreased microglial migration and Tau-deposit degradation. The P2Y12 signaling mediate the formation of migratory actin structures like- podosome and filopodia to exhibit chemotaxis and degrade Tau deposit. These beneficial roles of P2Y12 in microglial chemotaxis, actin network remodeling and Tau clearance can be intervened as a therapeutic target in AD.
Sections du résumé
BACKGROUND
BACKGROUND
Tau protein forms neurofibrillary tangles and becomes deposited in the brain during Alzheimer's disease (AD). Tau oligomers are the most reactive species, mediating neurotoxic and inflammatory activity. Microglia are the immune cells in the central nervous system, sense the extracellular Tau via various cell surface receptors. Purinergic P2Y12 receptor can directly interact with Tau oligomers and mediates microglial chemotaxis via actin remodeling. The disease-associated microglia are associated with impaired migration and express a reduced level of P2Y12, but elevate the level of reactive oxygen species and pro-inflammatory cytokines.
RESULTS
RESULTS
Here, we studied the formation and organization of various actin microstructures such as-podosome, filopodia and uropod in colocalization with actin nucleator protein Arp2 and scaffold protein TKS5 in Tau-induced microglia by fluorescence microscopy. Further, the relevance of P2Y12 signaling either by activation or blockage was studied in terms of actin structure formations and Tau deposits degradation by N9 microglia. Extracellular Tau oligomers facilitate the microglial migration via Arp2-associated podosome and filopodia formation through the involvement of P2Y12 signaling. Similarly, Tau oligomers induce the TKS5-associated podosome clustering in microglial lamella in a time-dependent manner. Moreover, the P2Y12 was evidenced to localize with F-actin-rich podosome and filopodia during Tau-deposit degradation. The blockage of P2Y12 signaling resulted in decreased microglial migration and Tau-deposit degradation.
CONCLUSIONS
CONCLUSIONS
The P2Y12 signaling mediate the formation of migratory actin structures like- podosome and filopodia to exhibit chemotaxis and degrade Tau deposit. These beneficial roles of P2Y12 in microglial chemotaxis, actin network remodeling and Tau clearance can be intervened as a therapeutic target in AD.
Identifiants
pubmed: 37221563
doi: 10.1186/s13578-023-01028-0
pii: 10.1186/s13578-023-01028-0
pmc: PMC10204346
doi:
Types de publication
Journal Article
Langues
eng
Pagination
95Subventions
Organisme : National Chemical Laboratory
ID : CSIR NCL MLP101726
Informations de copyright
© 2023. The Author(s).
Références
J Mol Neurosci. 2018 Nov;66(3):356-368
pubmed: 30267382
Cell. 2018 May 17;173(5):1073-1081
pubmed: 29775591
Glia. 2010 May;58(7):790-801
pubmed: 20091784
Neurobiol Aging. 2017 Oct;58:41-53
pubmed: 28697378
Front Pharmacol. 2017 Sep 25;8:661
pubmed: 28993732
J Cell Sci. 2006 Feb 15;119(Pt 4):769-81
pubmed: 16449321
J Immunol. 2010 Jan 15;184(2):1049-61
pubmed: 20018633
J Thromb Thrombolysis. 2020 Nov;50(4):874-885
pubmed: 32248335
Physiol Rev. 2014 Jan;94(1):235-63
pubmed: 24382887
PLoS One. 2012;7(8):e43859
pubmed: 22952790
Nat Rev Mol Cell Biol. 2011 Jun 23;12(7):413-26
pubmed: 21697900
Cell. 2017 Jun 15;169(7):1276-1290.e17
pubmed: 28602351
Signal Transduct Target Ther. 2021 Apr 17;6(1):160
pubmed: 33866328
J Cell Biol. 2008 Jul 14;182(1):157-69
pubmed: 18606851
Nat Commun. 2019 Nov 15;10(1):5171
pubmed: 31729386
Biol Cell. 2013 Jan;105(1):46-57
pubmed: 23106484
Biophys J. 2017 Feb 28;112(4):780-794
pubmed: 28256237
J Neuroinflammation. 2012 Nov 17;9:250
pubmed: 23158496
Cell Mol Neurobiol. 2021 Aug;41(6):1175-1181
pubmed: 32529542
Nat Neurosci. 2015 Nov;18(11):1584-93
pubmed: 26436904
J Cell Biol. 2019 Dec 2;218(12):4215-4235
pubmed: 31594807
Science. 2020 Jan 31;367(6477):528-537
pubmed: 31831638
Nat Cell Biol. 2014 Oct;16(10):931-41, 1-8
pubmed: 25218639
J Cell Sci. 2010 May 1;123(Pt 9):1427-37
pubmed: 20356925
Nat Commun. 2017 May 11;8:15295
pubmed: 28492240
Cell Rep. 2013 Dec 12;5(5):1456-68
pubmed: 24290759
J Immunol. 2012 Apr 15;188(8):3686-99
pubmed: 22442443
Int J Mol Sci. 2017 Apr 05;18(4):
pubmed: 28379162
Mol Biomed. 2021 Jun 10;2(1):17
pubmed: 35006431
Mol Biol Cell. 2009 Mar;20(5):1302-11
pubmed: 19144821
Thromb Haemost. 2013 Nov;110(5):903-9
pubmed: 23864155
Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(2):e80
pubmed: 25821842
Mol Cell Biol. 2006 May;26(9):3582-94
pubmed: 16611998
Front Cell Neurosci. 2018 Jul 10;12:172
pubmed: 30042659
Cell Rep. 2019 Jun 4;27(10):2895-2908.e4
pubmed: 31167136
Int J Mol Sci. 2020 Jan 20;21(2):
pubmed: 31968618
J Microsc. 2008 Sep;231(3):494-505
pubmed: 18755005
Front Neurol. 2013 Aug 15;4:112
pubmed: 23966973
Neuropharmacology. 2014 Jan;76 Pt A:1-8
pubmed: 24076336
Acta Neuropathol Commun. 2019 Jul 5;7(1):109
pubmed: 31277708
Semin Cell Dev Biol. 2020 Jun;102:81-89
pubmed: 31843255
Cancer Cell. 2005 Feb;7(2):155-65
pubmed: 15710328
Cytoskeleton (Hoboken). 2011 Dec;68(12):694-711
pubmed: 22021214
Brain Res Bull. 2019 Sep;151:38-45
pubmed: 30500565
J Cell Biol. 2003 May 26;161(4):697-705
pubmed: 12756237
Neuroscience. 2020 Nov 10;448:325-336
pubmed: 32941933
Brain. 2017 Jul 1;140(7):1900-1913
pubmed: 28541408
Immunity. 2020 Jan 14;52(1):167-182.e7
pubmed: 31883839
J Cell Biol. 2005 Jan 31;168(3):441-52
pubmed: 15684033
Mol Biomed. 2021 Feb 9;2(1):4
pubmed: 35006402
Brain Commun. 2021 Jan 29;3(1):fcab011
pubmed: 33644757
Annu Rev Immunol. 2017 Apr 26;35:441-468
pubmed: 28226226
Cell Death Dis. 2017 Mar 16;8(3):e2671
pubmed: 28300838
Am J Physiol Heart Circ Physiol. 2005 Jun;288(6):H3001-5
pubmed: 15695563
Mol Neurodegener. 2018 May 21;13(1):24
pubmed: 29784049
Eur J Cell Biol. 2006 Apr;85(3-4):195-202
pubmed: 16546562
Eur J Cell Biol. 2008 Sep;87(8-9):491-506
pubmed: 18417250
J Biol Chem. 2007 Sep 14;282(37):27392-27401
pubmed: 17623670
Sci Rep. 2018 Jan 11;8(1):524
pubmed: 29323185
Nat Commun. 2016 Mar 07;7:10905
pubmed: 26948129
Glia. 2017 Feb;65(2):375-387
pubmed: 27862351
Nat Rev Neurosci. 2014 Apr;15(4):209-16
pubmed: 24646669
Traffic. 2021 May;22(5):153-170
pubmed: 33527700
J Neuroinflammation. 2013 Jun 21;10:75
pubmed: 23786632
Brain Res Bull. 2016 Jan;120:41-57
pubmed: 26551061
Methods Mol Biol. 2017;1523:3-20
pubmed: 27975241
J Neurosci. 2019 Nov 20;39(47):9453-9464
pubmed: 31597724
J Mol Neurosci. 2018 Aug;65(4):480-490
pubmed: 29982964
Cytoskeleton (Hoboken). 2013 Oct;70(10):572-89
pubmed: 23804547
J Alzheimers Dis. 2014;40 Suppl 1:S97-S111
pubmed: 24603946
Cytoskeleton (Hoboken). 2010 Sep;67(9):573-85
pubmed: 20617518
J Pain Res. 2017 Jul 26;10:1755-1767
pubmed: 28794655
J Neuroinflammation. 2020 Jan 8;17(1):10
pubmed: 31915009
Mol Cell Neurosci. 2009 Dec;42(4):382-90
pubmed: 19733667
Aging Clin Exp Res. 2017 Oct;29(5):821-831
pubmed: 27718173
Cell Mol Life Sci. 2019 Oct;76(19):3681-3694
pubmed: 31093687